Influenza Pneumonia
Conditions
Interventions
Group 2:Arbidol + Oseltamivir
Group 1:Oseltamivir
Sponsors
Shulan (Hangzhou) Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) willing to give written informed consent; 2) at least 18 years of age; 3) nasopharyngeal swabs or respiratory secretions influenza rapid antigen (or nucleic acid) testing positive; 4) clinical diagnosis of viral pneumonia, or lung Department Imaging (CT) in line with viral pneumonia
Exclusion criteria
Exclusion criteria: 1) the medicines have allergies and / or severe anaphylactic shock by mass; 2) researchers believe that the subject will affect the safety of a history of severe heart disease, arrhythmia or clinically significant; 3) rapid respiratory rate, dyspnea, cyanosis, domestic demand is expected to two hours on a mechanical ventilator support; 4) changes in consciousness, appears unresponsive, drowsiness, restlessness, convulsions; 5) severe vomiting, diarrhea; 6) and liver function abnormalities not related to the underlying disease; 7) renal function independent of the underlying disease of abnormal; 8) serious secondary bacterial pneumonia caused by other pathogens or determining clinician pneumonia unsuitable enrolled in the study; 9) determines foundation clinician domestic exacerbation 24 hours on a mechanical ventilator support: Before 10) screening of the other 2d received antiviral therapy; 11) women who are pregnant or breast-feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| influenza nucleic acid detection; | — |
Countries
China
Contacts
Public ContactLingling Tang
Shulan (Hangzhou) Hospital
Outcome results
None listed